FDA APPROVES FIRST THERAPY FOR PATIENTS WITH LUNG AND THYROID CANCERS WITH A CERTAIN GENETIC MUTATION OR FUSION
The U.S. Food and Drug Administration (FDA), approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). Retevmo is the first […]
